Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axonics, Inc.
  6. Summary
    AXNX   US05465P1012

AXONICS, INC.

(AXNX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
70.44(c) 70.52(c) 71.32(c) 72.44(c) 68.87 Last
703 325 887 081 647 565 1 866 258 896 417 Volume
-2.84% +0.11% +1.13% +1.57% -4.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 187 M - -
Net income 2021 -82,3 M - -
Net cash position 2021 39,5 M - -
P/E ratio 2021 -37,6x
Yield 2021 -
Sales 2022 254 M - -
Net income 2022 -49,2 M - -
Net cash position 2022 67,3 M - -
P/E ratio 2022 -65,7x
Yield 2022 -
Capitalization 3 339 M 3 339 M -
EV / Sales 2021 17,6x
EV / Sales 2022 12,9x
Nbr of Employees 416
Free-Float 88,1%
More Financials
Company
Axonics, Inc., formerly Axonics Modulation Technologies, Inc., is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses... 
More about the company
Ratings of Axonics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AXONICS, INC.
09/14INSIDER SELL : Axonics
MT
09/14MEDTRONIC : Says US Patent Office Rejects Axonics' Challenge to Bladder Device P..
MT
09/13AXONICS : reg; Announces Partial Decision on Inter Partes Review Proceedings
BU
08/27AXONICS : reg; to Participate in Upcoming Investor Conferences
BU
08/09AXONICS : Morgan Stanley Adjusts Price Target on Axonics to $74 From $62, Mainta..
MT
08/06AXONICS : Piper Sandler Adjusts Axonics' Price Target to $78 From $75, Maintains..
MT
08/06AXONICS : Barclays Adjusts Axonics' Price Target to $79 From $74, Maintains Over..
MT
08/05AXONICS : Q2 Earnings Snapshot
AQ
08/05AXONICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/05AXONICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/05Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2021
CI
08/05AXONICS : Earnings Flash (AXNX) AXONICS Reports Q2 Revenue $45.9M, vs. Street Es..
MT
08/05AXONICS : Earnings Flash (AXNX) AXONICS Posts Q2 Loss $-0.59, vs. Street Est of ..
MT
08/05AXONICS : reg; Reports Second Quarter 2021 Financial Results
BU
08/05Axonics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
More news
News in other languages on AXONICS, INC.
09/14Medtronic déclare que l'Office américain des brevets rejette la contestation ..
2020AXONICS MODULATION TECHNOLOGIES : « gibt Ergebnisse einer Erhebung bei Patienten..
2020AXONICS MODULATION TECHNOLOGIES : « publie les résultats cliniques sur 2áans de ..
2020AXONICS MODULATION TECHNOLOGIES : « berichtet 2-Jahres-Ergebnisse aus der ARTISA..
2020AXONICS MODULATION TECHNOLOGIES : NICE empfiehlt Axonics« r-SNM System zur Behan..
More news
Analyst Recommendations on AXONICS, INC.
More recommendations
Chart AXONICS, INC.
Duration : Period :
Axonics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXONICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 72,44 $
Average target price 78,40 $
Spread / Average Target 8,23%
EPS Revisions
Managers and Directors
Raymond Wayne Cohen Chief Executive Officer & Director
Danny L. Dearen President & Chief Financial Officer
Michael H. Carrel Chairman
Guang Qiang Jiang Chief Technology Officer
Karen Noblett Chief Medical Officer
Sector and Competitors